MedTrace Logo

Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms

NCT05455294 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2026-01-28

No results posted yet for this study

Summary

The purpose of this research study is to test the safety of a new three drug combination of navitoclax, decitabine, and venetoclax to treat advanced myeloid malignancies.

The names of the drugs involved in this study are:

* Venetoclax
* Decitabine
* Navitoclax

Conditions

Interventions

DRUG

Navitoclax

See Arm Description

DRUG

Venetoclax

See Arm Description

DRUG

Decitabine

See Arm Description

Sponsors & Collaborators

  • AbbVie

    collaborator INDUSTRY

  • Jacqueline Garcia, MD

    lead OTHER

Principal Investigators

  • Jacqueline S Garcia, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-18
Primary Completion
2024-04-17
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05455294 on ClinicalTrials.gov